NCOA5 is correlated with progression and prognosis in luminal breast cancer
Nuclear receptor coactivator 5 (NCOA5) is known to modulate ERα-mediated transcription and has been found to be involved in the progression of several malignancies. However, the potential correlation between NCOA5 and clinical outcome in patients with luminal breast cancer remains unknown. In the pr...
Gespeichert in:
| Veröffentlicht in: | Biochemical and biophysical research communications 2017-01, Vol.482 (2), p.253-256 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 256 |
|---|---|
| container_issue | 2 |
| container_start_page | 253 |
| container_title | Biochemical and biophysical research communications |
| container_volume | 482 |
| creator | Ye, Xiao-He Huang, Du-Ping Luo, Rong-Cheng |
| description | Nuclear receptor coactivator 5 (NCOA5) is known to modulate ERα-mediated transcription and has been found to be involved in the progression of several malignancies. However, the potential correlation between NCOA5 and clinical outcome in patients with luminal breast cancer remains unknown. In the present study, we demonstrated that NCOA5 was significantly up-regulated in luminal breast cancer tissues compared with adjacent non-cancerous tissues both in validated cohort and TCGA cohort. Moreover, Kaplan-Meier analysis indicated that patients with high NOCA5 expression had significantly lower overall survival (P = 0.021). Cox regression analysis indicated that the high NOCA5 expression was independent high risk factor as well as old age (>60) and HER-2 expression (P = 0.039; P = 0.003; P = 0.005; respectively). This study provides new insights and evidences that NOCA5 over-expression was significantly correlated with progression and prognosis in luminal breast cancer. However, the precise cellular mechanisms for NOCA5 in luminal breast cancer need to be further explored.
•NCOA5 is significantly over-expressed in human luminal breast cancer tissues.•NOCA5 was involved in the progression of luminal breast cancer.•NCOA5 can predict the progression of luminal breast cancer. |
| doi_str_mv | 10.1016/j.bbrc.2016.11.051 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22696751</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X16319052</els_id><sourcerecordid>1841129118</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-66636235e5423e010b7e7b50b6e04f4ffc8461000427173cfa366717c5044c173</originalsourceid><addsrcrecordid>eNp9kMFO3DAQhq2qqCzbvgCHKlIvvSTMOI6TlbisVm1BILhQqTfLcSbgVdbe2lkQb4_DLhw5eTz65tevj7FThAIB5dm6aNtgCp7mArGACj-xGcICco4gPrMZAMicL_DfMTuJcQ2AKOTiCzvmdSPqEpsZu7pZ3S6rzMbM-BBo0CN12ZMdH7Jt8PeBYrTeZdp1r3_nYyKty4bdxjo9ZG0gHcfMaGcofGVHvR4ifTu8c_b396-71UV-ffvncrW8zk3ZiDGXUpaSlxVVgpcECG1NdVtBKwlEL_reNEJi6i54jXVpel1KmSZTgRAmbebsxz7Xx9GqaOxI5sF458iMinO5kHWFifq5p1Lx_zuKo9rYaGgYtCO_iwobgZjkYJNQvkdN8DEG6tU22I0OzwpBTarVWk2q1aRaISp4zf9-yN-1G-reT97cJuB8D1By8WgpTFUpiepsmJp23n6U_wKlJoy7</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1841129118</pqid></control><display><type>article</type><title>NCOA5 is correlated with progression and prognosis in luminal breast cancer</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Ye, Xiao-He ; Huang, Du-Ping ; Luo, Rong-Cheng</creator><creatorcontrib>Ye, Xiao-He ; Huang, Du-Ping ; Luo, Rong-Cheng</creatorcontrib><description>Nuclear receptor coactivator 5 (NCOA5) is known to modulate ERα-mediated transcription and has been found to be involved in the progression of several malignancies. However, the potential correlation between NCOA5 and clinical outcome in patients with luminal breast cancer remains unknown. In the present study, we demonstrated that NCOA5 was significantly up-regulated in luminal breast cancer tissues compared with adjacent non-cancerous tissues both in validated cohort and TCGA cohort. Moreover, Kaplan-Meier analysis indicated that patients with high NOCA5 expression had significantly lower overall survival (P = 0.021). Cox regression analysis indicated that the high NOCA5 expression was independent high risk factor as well as old age (>60) and HER-2 expression (P = 0.039; P = 0.003; P = 0.005; respectively). This study provides new insights and evidences that NOCA5 over-expression was significantly correlated with progression and prognosis in luminal breast cancer. However, the precise cellular mechanisms for NOCA5 in luminal breast cancer need to be further explored.
•NCOA5 is significantly over-expressed in human luminal breast cancer tissues.•NOCA5 was involved in the progression of luminal breast cancer.•NCOA5 can predict the progression of luminal breast cancer.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2016.11.051</identifier><identifier>PMID: 27847318</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; Age Distribution ; Aged ; Aged, 80 and over ; ANIMAL TISSUES ; Biomarkers, Tumor - metabolism ; Breast Neoplasms - diagnosis ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; China - epidemiology ; Disease Progression ; Female ; Humans ; Incidence ; Luminal breast cancer ; MAMMARY GLANDS ; Middle Aged ; NCOA5 ; NEOPLASMS ; Nuclear Receptor Coactivators - metabolism ; PHENOBARBITAL ; PLANT TISSUES ; Prognosis ; REGRESSION ANALYSIS ; Reproducibility of Results ; Risk Factors ; Sensitivity and Specificity ; Statistics as Topic ; Survival Rate</subject><ispartof>Biochemical and biophysical research communications, 2017-01, Vol.482 (2), p.253-256</ispartof><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-66636235e5423e010b7e7b50b6e04f4ffc8461000427173cfa366717c5044c173</citedby><cites>FETCH-LOGICAL-c384t-66636235e5423e010b7e7b50b6e04f4ffc8461000427173cfa366717c5044c173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbrc.2016.11.051$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,781,785,886,3551,27926,27927,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27847318$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22696751$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Ye, Xiao-He</creatorcontrib><creatorcontrib>Huang, Du-Ping</creatorcontrib><creatorcontrib>Luo, Rong-Cheng</creatorcontrib><title>NCOA5 is correlated with progression and prognosis in luminal breast cancer</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>Nuclear receptor coactivator 5 (NCOA5) is known to modulate ERα-mediated transcription and has been found to be involved in the progression of several malignancies. However, the potential correlation between NCOA5 and clinical outcome in patients with luminal breast cancer remains unknown. In the present study, we demonstrated that NCOA5 was significantly up-regulated in luminal breast cancer tissues compared with adjacent non-cancerous tissues both in validated cohort and TCGA cohort. Moreover, Kaplan-Meier analysis indicated that patients with high NOCA5 expression had significantly lower overall survival (P = 0.021). Cox regression analysis indicated that the high NOCA5 expression was independent high risk factor as well as old age (>60) and HER-2 expression (P = 0.039; P = 0.003; P = 0.005; respectively). This study provides new insights and evidences that NOCA5 over-expression was significantly correlated with progression and prognosis in luminal breast cancer. However, the precise cellular mechanisms for NOCA5 in luminal breast cancer need to be further explored.
•NCOA5 is significantly over-expressed in human luminal breast cancer tissues.•NOCA5 was involved in the progression of luminal breast cancer.•NCOA5 can predict the progression of luminal breast cancer.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>Age Distribution</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>ANIMAL TISSUES</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>China - epidemiology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Luminal breast cancer</subject><subject>MAMMARY GLANDS</subject><subject>Middle Aged</subject><subject>NCOA5</subject><subject>NEOPLASMS</subject><subject>Nuclear Receptor Coactivators - metabolism</subject><subject>PHENOBARBITAL</subject><subject>PLANT TISSUES</subject><subject>Prognosis</subject><subject>REGRESSION ANALYSIS</subject><subject>Reproducibility of Results</subject><subject>Risk Factors</subject><subject>Sensitivity and Specificity</subject><subject>Statistics as Topic</subject><subject>Survival Rate</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFO3DAQhq2qqCzbvgCHKlIvvSTMOI6TlbisVm1BILhQqTfLcSbgVdbe2lkQb4_DLhw5eTz65tevj7FThAIB5dm6aNtgCp7mArGACj-xGcICco4gPrMZAMicL_DfMTuJcQ2AKOTiCzvmdSPqEpsZu7pZ3S6rzMbM-BBo0CN12ZMdH7Jt8PeBYrTeZdp1r3_nYyKty4bdxjo9ZG0gHcfMaGcofGVHvR4ifTu8c_b396-71UV-ffvncrW8zk3ZiDGXUpaSlxVVgpcECG1NdVtBKwlEL_reNEJi6i54jXVpel1KmSZTgRAmbebsxz7Xx9GqaOxI5sF458iMinO5kHWFifq5p1Lx_zuKo9rYaGgYtCO_iwobgZjkYJNQvkdN8DEG6tU22I0OzwpBTarVWk2q1aRaISp4zf9-yN-1G-reT97cJuB8D1By8WgpTFUpiepsmJp23n6U_wKlJoy7</recordid><startdate>20170108</startdate><enddate>20170108</enddate><creator>Ye, Xiao-He</creator><creator>Huang, Du-Ping</creator><creator>Luo, Rong-Cheng</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20170108</creationdate><title>NCOA5 is correlated with progression and prognosis in luminal breast cancer</title><author>Ye, Xiao-He ; Huang, Du-Ping ; Luo, Rong-Cheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-66636235e5423e010b7e7b50b6e04f4ffc8461000427173cfa366717c5044c173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>Age Distribution</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>ANIMAL TISSUES</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>China - epidemiology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Luminal breast cancer</topic><topic>MAMMARY GLANDS</topic><topic>Middle Aged</topic><topic>NCOA5</topic><topic>NEOPLASMS</topic><topic>Nuclear Receptor Coactivators - metabolism</topic><topic>PHENOBARBITAL</topic><topic>PLANT TISSUES</topic><topic>Prognosis</topic><topic>REGRESSION ANALYSIS</topic><topic>Reproducibility of Results</topic><topic>Risk Factors</topic><topic>Sensitivity and Specificity</topic><topic>Statistics as Topic</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ye, Xiao-He</creatorcontrib><creatorcontrib>Huang, Du-Ping</creatorcontrib><creatorcontrib>Luo, Rong-Cheng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ye, Xiao-He</au><au>Huang, Du-Ping</au><au>Luo, Rong-Cheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NCOA5 is correlated with progression and prognosis in luminal breast cancer</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2017-01-08</date><risdate>2017</risdate><volume>482</volume><issue>2</issue><spage>253</spage><epage>256</epage><pages>253-256</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>Nuclear receptor coactivator 5 (NCOA5) is known to modulate ERα-mediated transcription and has been found to be involved in the progression of several malignancies. However, the potential correlation between NCOA5 and clinical outcome in patients with luminal breast cancer remains unknown. In the present study, we demonstrated that NCOA5 was significantly up-regulated in luminal breast cancer tissues compared with adjacent non-cancerous tissues both in validated cohort and TCGA cohort. Moreover, Kaplan-Meier analysis indicated that patients with high NOCA5 expression had significantly lower overall survival (P = 0.021). Cox regression analysis indicated that the high NOCA5 expression was independent high risk factor as well as old age (>60) and HER-2 expression (P = 0.039; P = 0.003; P = 0.005; respectively). This study provides new insights and evidences that NOCA5 over-expression was significantly correlated with progression and prognosis in luminal breast cancer. However, the precise cellular mechanisms for NOCA5 in luminal breast cancer need to be further explored.
•NCOA5 is significantly over-expressed in human luminal breast cancer tissues.•NOCA5 was involved in the progression of luminal breast cancer.•NCOA5 can predict the progression of luminal breast cancer.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27847318</pmid><doi>10.1016/j.bbrc.2016.11.051</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-291X |
| ispartof | Biochemical and biophysical research communications, 2017-01, Vol.482 (2), p.253-256 |
| issn | 0006-291X 1090-2104 |
| language | eng |
| recordid | cdi_osti_scitechconnect_22696751 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | 60 APPLIED LIFE SCIENCES Age Distribution Aged Aged, 80 and over ANIMAL TISSUES Biomarkers, Tumor - metabolism Breast Neoplasms - diagnosis Breast Neoplasms - metabolism Breast Neoplasms - mortality China - epidemiology Disease Progression Female Humans Incidence Luminal breast cancer MAMMARY GLANDS Middle Aged NCOA5 NEOPLASMS Nuclear Receptor Coactivators - metabolism PHENOBARBITAL PLANT TISSUES Prognosis REGRESSION ANALYSIS Reproducibility of Results Risk Factors Sensitivity and Specificity Statistics as Topic Survival Rate |
| title | NCOA5 is correlated with progression and prognosis in luminal breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T21%3A01%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NCOA5%20is%20correlated%20with%20progression%20and%20prognosis%20in%20luminal%20breast%20cancer&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Ye,%20Xiao-He&rft.date=2017-01-08&rft.volume=482&rft.issue=2&rft.spage=253&rft.epage=256&rft.pages=253-256&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2016.11.051&rft_dat=%3Cproquest_osti_%3E1841129118%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1841129118&rft_id=info:pmid/27847318&rft_els_id=S0006291X16319052&rfr_iscdi=true |